<DOC>
	<DOCNO>NCT02080533</DOCNO>
	<brief_summary>Pulmonary arterial hypertension ( PAH ) chronic illness characterize increase pulmonary pressure result right heart failure premature death . Common symptoms impair quality life function dyspnea , fatigue sleep disturbance . This trio symptoms highly prevalent form symptom cluster ( 2 symptom co-occur ) PAH . From biological , proinflammatory cytokine implicate dyspnea , fatigue sleep disturbance ; activation sympathetic nervous system ( SNS ) inherent inflammatory process PAH contribute pathophysiology , link symptom cluster investigate . One novel , treatment symptom cluster slow-paced respiration therapy use FDA-approved device , RESPeRATE . The device contain headphone sensor attache chest detect inhalation exhalation . Musical tone synchronize respiratory cycle slowly guide user decrease respiration . RESPeRATE moderate effect SNS ; lower blood pressure ; improve functional capacity ejection fraction ; significantly decrease pulmonary pressure leave heart failure . The investigator enroll 10 woman PAH use RESPeRATE device perform slow-paced respiration 15 minute per day 8 week determine feasibility effect SNS inflammatory activity symptom cluster . The investigator 's overall hypothesis , compare baseline , eight week therapy woman PAH receive slow-based respiration therapy low SNS activity inflammatory level , improve dyspnea , fatigue sleep disturbance .</brief_summary>
	<brief_title>Feasibility Slow-paced Respiration Therapy Treatment Symptom Cluster Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<criteria>Previous documentation mean pulmonary artery pressure &gt; 25 mm Hg pulmonary capillary wedge pressure ( left ventricular enddiastolic pressure ) &lt; 16 mm Hg PVR &gt; 3 WU time study entry . Women WHO Group I PAH ( idiopathic , heritable , associated connective tissue disease , congenital heart disease , anorexigens HIV ) Targeted PAH therapy stable dose 3 month Age &gt; 21 year Ability perform six minute walk test without limitation musculoskeletal function coordination . Informed consent Age &lt; 21 Hypotension ( blood pressure &lt; 90/60 mmHg ) Pregnancy Chronic Fatigue Syndrome ( current history ) Known sleep disorder ( obstructive sleep apnea , restless leg syndrome , narcolepsy , current history ) Hospitalized acutely ill Major Depression ( current history ) Lung transplant recipient</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>symptom</keyword>
	<keyword>dyspnea</keyword>
	<keyword>fatigue</keyword>
	<keyword>sleep</keyword>
</DOC>